Prestige

Prestige Biopharma is a Singapore-headquartered biopharmaceutical company focused on biosimilars and novel antibody therapeutics, with additional work in vaccines and diagnostics. The company’s lead commercialized asset is Tuznue, a trastuzumab biosimilar approved in the European Union, while Vasforda, a bevacizumab biosimilar, is in filing preparation following late-stage development. Prestige is also advancing first-in-class antibody programs including ulenistamab for pancreatic and ovarian cancer and preclinical anti-CTHRC1 programs for solid tumors and fibrotic disease. Its broader platform includes a sizable biosimilar portfolio and group manufacturing capabilities through affiliated entities in Korea, including the ALITA Smart BioFactory and the Prestige Biopharma IDC antibody R&D hub. Overall, the company combines commercial-stage biosimilars with earlier-stage oncology biologics and enabling R&D and manufacturing infrastructure.